781652-57-1
781652-57-1
Chemical Structure
CDPPB
- CAS No.: 781652-57-1
- Formula:C23H16N4O
- Molecular Weight:364.40
IUPAC Name: 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
InChIKey: BKUIZWILNWHFHD-UHFFFAOYSA-N
SMILES: O=C(NC1=CC(C2=CC=CC=C2)=NN1C3=CC=CC=C3)C4=CC=CC(C#N)=C4
Biological Activity: CDPPB is a selective, orally active and brain-penetrant mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CDPPB | 98.01% | CDPPB is a selective, orally active and brain-penetrant mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kinney GG, et, al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther. 2005 Apr; 313(1):199-206. [Content Brief]
- [2]. Guan DF, et al. The mGluR5 positive allosteric modulator CDPPB inhibits SO₂-induced protein radical formation and mitochondrial dysfunction through activation of Akt in mouse hippocampal HT22 cells. Cell Mol Neurobiol. 2015 May;35(4):573-83. [Content Brief]
- [3]. Chen T, et al. Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC-dependent activation of MEK/ERK pathway. Neurochem Res. 2012 May;37(5):983-90. [Content Brief]
- [4]. Horio M, et al. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundam Clin Pharmacol. 2013 Oct;27(5):483-8.
- [5]. Płoska A, et al. Neurochemical changes underlying cognitive impairment in olfactory bulbectomized rats and the impact of the mGlu5-positive allosteric modulator CDPPB. Brain Res. 2021 Oct 1;1768:147577. [Content Brief]
- [6]. Doria JG, et al. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol Dis. 2015 Jan;73:163-73. [Content Brief]
- [7]. Zhang L, et al. Post-stress Social Interaction and 3-Cyano-N-(1,3-Diphenyl-1H-Pyrazol-5-yl) Benzamide Treatment Attenuate Depressive-like Behavior Induced by Repeated Social Defeat Stress. Neuroscience. 2024 Feb 6;538:11-21. [Content Brief]
- [8]. Miller-Rhodes P, et al. Sex-specific behavioral impairments produced by neonatal exposure to MK-801 are partially reversed by adolescent CDPPB treatment. Neurotoxicology and Teratology, 2022, 89: 107053.
- [9]. Bellozi PMQ, et al. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology. 2019 Dec 1;160:107785. [Content Brief]
